RAS Webinar Videos

2019

• Dr. Frank McCormick, "History of Biology and Medicine Series: RAS Proteins in Human Disease"

  As part of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's History of Biology and Medicine lecture series, Dr. Frank McCormick summarizes four decades of RAS research and explains the role of RAS proteins in human diseases.

• Dr. Pasi A Jänne, "A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors"

  Dr. Pasi A Jänne presents clinical trial data of MRTX849, which specifically targets KRAS G12C mutant tumors.

• Dr. Alan Ho, "Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations"

  Dr. Alan Ho discusses clinical trial data of tipifarnib, a drug that targets HRAS.

2018

• Dr. Frank McCormick, "The RAS Initiative on National Public Radio"

  The NCI RAS Initiative was featured on National Public Radio on March 9, 2018.

2017

• Dr. Frank McCormick, "The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research"

  At the Annual Meeting of the American Association for Cancer Research, Frank McCormick, leader of the NCI RAS Initiative, summarizes recent RI activities.

• Dr. Bert Vogelstein, "The Road to Cancer Cures - Discover, Predict, Prevent, and Treat"

  Bert Vogelstein reflects on why we can cure cancer in mice but not so well in people, and on the sources of mutations in cancer.

• Dr. Charles Sawyers, "New Twists on Cancer Drug Resistance"

  As drugs that attack RAS directly become available, cancers will inevitably develop resistance. What Charles Sawyers tells us about resistance mechanisms in prostate cancer gives us hope that resistance to RAS therapies can be overcome.

2015

• Free videos from the 2015 AACR Annual Meeting

  All the scientific presentations from the 2015 Annual Meeting of the American Association for Cancer Research in Philadelphia, USA that are available for viewing without charge may now be found on the AACR web site.

• Drug Screens Targeting KRAS

  Dr. Matt Holderfield of the Frederick National Lab describes the development of multiple drug screening platforms targeting KRAS in the NCI RAS Initiative. April 21, 2015 at the AACR Annual Meeting, Philadelphia, USA.

• How Do the Mutations Underlying Cancers Arise?

  Dr. Michael Stratton of the Welcome Trust Sanger Institute, Cambridge, UK describes new insights into the mutational processes that drive cancers. (Dr. Stratton's scientific remarks begin five minutes into the video.) April 19, 2015 at the AACR Annual Meeting, Philadelphia USA.

• Demystifying Medicine 2015 - RAS: A Cancer Mechanism and Target

  Dr. Susan Bates of the NCI's Developmental Therapeutics Branch and Dr. Frank McCormick, science advisor to the NCI RAS Initiative, describe the impact of RAS mutations on human health, and new information on regulation of RAS signaling. February 10, 2015 at the National Cancer Institute, Bethesda, Maryland

2014

• Dr. Frank McCormick, "New Targets on the RAS Pathway"

  Dr. Frank McCormick describes recent experiments to understand KRAS signaling in cancer at the AACR Annual Meeting, April 5, 2014, San Diego, California USA

2011: Structural Aspects of RAS GTPases

• Dr. Alfred Wittinghofer, "GTP-binding Proteins as Molecular Switches", Part 1

  Dr. Alfred Wittinghofer explains how solving the three-dimensional structure of RAS and other G-proteins allowed him to understand the conserved mechanism by which G-proteins can act as switches. June 19, 2011

• Dr. Alfred Wittinghofer, "GTP-binding Proteins as Molecular Switches", Part 2

  In the second part of Dr. Wittinghofer's talk he explains the link between GTPases and disease. June 19, 2011